SIGNALS◐ DEVELOPINGI · Intelligence◆ Concentrating
Novartis buys Myricx Bio for next-gen ADC payloads
Jul 6, 2026SOURCE: myricxbio.com
SO WHAT
The window is still open for strategic control of the biology stack, and this deal pushes another critical layer toward concentration.
Novartis will acquire Myricx Bio to develop a novel NMTi platform for oncology ADC payloads. The signal is straightforward: more of the drug stack is moving under a few balance sheets.
This is Negative Resistance’s reframed reading of a reported signal. The headline and analysis above are our interpretation through the thousand-day-window lens. The original reporting lives at the source linked above.